93 related articles for article (PubMed ID: 321684)
1. Activity of tumor-associated lymphoid cells at short intervals after administration of irradiated syngeneic and allogeneic tumor cells.
Schick B; Berke G
J Immunol; 1977 Mar; 118(3):986-91. PubMed ID: 321684
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated lymphoid cells: analysis of host cells that bind to syngeneic and allogeneic tumor cells shortly after tumor administration.
Schick B; Berke B
Transplant Proc; 1977 Mar; 9(1):1157-60. PubMed ID: 867485
[TBL] [Abstract][Full Text] [Related]
3. Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
Matsumoto T; Himeno K; Mitani M; Mori K; Miake S; Nomoto K
J Clin Lab Immunol; 1986 Feb; 19(2):83-9. PubMed ID: 3083105
[TBL] [Abstract][Full Text] [Related]
4. Studies of the mechanisms for the induction of in vivo tumor immunity. IV. Enhancement of the in vitro generation of secondary cell-mediated cytotoxic response by normal peritoneal macrophages and their culture supernatants.
Igarashi T; Rodrigues D; Ting CC
J Immunol; 1979 Apr; 122(4):1519-27. PubMed ID: 156217
[TBL] [Abstract][Full Text] [Related]
5. Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to Leukemia-associated antigens.
Ting CC; Law LW
J Immunol; 1977 Apr; 118(4):1259-64. PubMed ID: 191534
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
9. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
10. Humoral regulation of cell-mediated immunity to syngeneic tumor.
Ting CC
Cancer Res; 1976 Oct; 36(10):3695-701. PubMed ID: 953995
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
12. Tryptophan degradation in transplanted tumor cells undergoing rejection.
Yoshida R; Park SW; Yasui H; Takikawa O
J Immunol; 1988 Oct; 141(8):2819-23. PubMed ID: 3262668
[TBL] [Abstract][Full Text] [Related]
13. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
14. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S
Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
[TBL] [Abstract][Full Text] [Related]
15. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice.
Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G
Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell destruction by cytotoxic T lymphocytes: the basis of reduced antitumor cell activity in syngeneic hosts.
Fishelson Z; Berke G
J Immunol; 1981 May; 126(5):2048-52. PubMed ID: 6783702
[TBL] [Abstract][Full Text] [Related]
17. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
[TBL] [Abstract][Full Text] [Related]
18. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
[TBL] [Abstract][Full Text] [Related]
19. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
Gordon WC; Prager MD
Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
[TBL] [Abstract][Full Text] [Related]
20. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
